🔎 Trials Near Me

Home › Leukemia › New York

Pag-aaral pangklinika para sa Leukemia sa New York

26 pag-aaral para sa Leukemia ang naghahanap ng mga kalahok sa mga site sa New York.

Mga Lungsod sa New York

Opisyal na teksto ng pag-aaral (English)

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 4, Buffalo
  • Quetzal Site 2, The Bronx
Nagre-recruitPhase 3
Edad 18 hanggang 71 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07504458

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Weill Cornell, New York
  • Clinical Research Allicance, Westbury
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06824168

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Montefiore Medical Center, New York
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04065399

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

  • Memorial Sloan Kettering Cancer Center, New York
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06229912

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  • Research Site, Rochester
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

  • Columbia University Medical Center New York Presbyterian, New York
Nagre-recruitPhase 2
Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07354074

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Northwell Health, LLC PRIME, Lake Success
  • Memorial Sloan Kettering Cancer Center, New York
  • at 3 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • State University of New York at Buffalo, Buffalo
  • Icahn School of Medicine at Mount Sinai, New York
  • Columbia University, New York
  • at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, New York
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT06137118

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • New York Medical College, Valhalla
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

  • Albany Medical Center, Albany
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 30 · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT04968834

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Weill Cornell Medicine - New York Presbyterian Hospital, New York
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443

Hairy Cell Leukemia Patient Data Registry

  • University of Rochester /Wilmot Cancer Institute, Rochester
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT02560883

Integrated Cancer Repository for Cancer Research

  • C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
  • Faxton St. Luke's Healthcare, Mohawk Valley, Utica
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699

CD4CAR for CD4+ Leukemia and Lymphoma

  • Albert Einstein Health Network, New York
Nagre-recruitPhase 1
Edad 12 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT03829540

A Study of Revumenib and Mezigdomide in People With Leukemia

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • at 1 pa
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT07356154

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site 1, New York
  • Dren Investigational Site 2, New York
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT05475925

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (All protocol activities), Commack
  • Memorial Sloan Kettering Westchester (All protocol activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activities), New York
  • at 1 pa
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update May 26, 2026 · NCT07052916

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
  • University of Rochester, Rochester
  • Stony Brook University Medical Center, Stony Brook
  • at 1 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 18, 2026 · NCT01790152

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Nagre-recruitPhase 2
Hanggang edad 26 · Lahat ng kasarian · Na-update May 14, 2026 · NCT07566377

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • New York University Langone Hospital - Long Island, Mineola
  • Perlmutter Cancer Center - 34th Street, New York
  • at 2 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT04256317

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • New York - Presbyterian / Weill Cornell Medicine, New York
  • Mount Sinai - Ruttenberg Treatment Center, New York
  • at 2 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • Memorial Sloan Kettering Cancer Center, New York
  • at 1 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Lahat ng edad · Lahat ng kasarian · Na-update Ene 23, 2026 · NCT00582621

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Buffalo
  • Massive Bio SYNERGY-AI site, Hempstead
  • Massive Bio SYNERGY-AI site, Manhasset
  • at 2 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2025 · NCT06501196

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.